A Weight-Loss Drug, Approved for a Liver Disease

Semaglutide became the first GLP-1 medicine cleared for MASH — and only the second drug of any kind for a disease that long had none.

On August 15, 2025, the FDA granted accelerated approval to Wegovy for adults with noncirrhotic MASH — metabolic dysfunction–associated steatohepatitis — and moderate-to-advanced fibrosis, to be used alongside diet and exercise. The Wegovy MASH approval marked two firsts: the first GLP-1 receptor agonist ever approved for a liver disease, and only the second drug of any class for MASH, after resmetirom (Rezdiffra) in March 2024.

Why MASH needed a drug

MASH is the aggressive form of fatty liver disease. Fat drives inflammation, inflammation lays down scar tissue, and scarring can progress to cirrhosis, liver failure, and cancer. It affects roughly one in twenty American adults, frequently without symptoms until it is advanced, and it clusters with obesity and type 2 diabetes. For years, treatment meant lifestyle change and hoping — the pharmacy shelf was nearly bare.

What “accelerated approval” means here

Accelerated approval is a specific kind of yes, and understanding it matters. The FDA acted on the 72-week interim results of the ESSENCE trial: resolution of steatohepatitis without worsening fibrosis in about 63% of semaglutide patients versus 34% on placebo, and fibrosis improvement in roughly 37% versus 22%. Those are surrogate endpoints — improvements measured on liver biopsy that are reasonably likely to predict clinical benefit.

The approval is conditional on confirming that prediction. Novo Nordisk must show, in ESSENCE’s 240-week phase reading out around 2029, that the biopsy gains translate into what patients ultimately care about: fewer transplants, fewer liver failures, fewer deaths. If that confirmation falls short, the approval can be withdrawn.

The specifics of the label

The indication is deliberately bounded. It covers noncirrhotic MASH with fibrosis stages F2 to F3 — moderate to advanced scarring, but not established cirrhosis. Patients with cirrhosis were outside the trial and are outside the label. This precision protects against overreach: the evidence supports use in a defined window, and the approval stays inside it.

Why the approval is a milestone

The significance is practical as much as scientific. MASH travels with the exact metabolic conditions semaglutide already treats. A single medicine that addresses weight, glucose, and now the liver simplifies care for patients who often carry all three — and reduces the pill burden and appointment load that fragmented treatment imposes.

It also validates a broader idea: that metabolic drugs can reach into organs and reverse disease, not merely manage risk factors. The liver is the proof of concept—kidney and cardiovascular indications for the class point in the same direction.

What it means

The Wegovy MASH approval gives hepatologists a real tool where they had almost none, within clear limits. It is accelerated, not final; the survival question remains open until the long-term data arrive. For patients with moderate-to-advanced MASH, it means a treatment exists — one many of them may already be taking for other reasons.

The label’s fine print is, as ever, the medicine. But the headline is worth stating plainly: a drug the public knows from weight loss now carries an FDA approval to treat a serious liver disease.

Frequently asked questions

Is Wegovy approved for liver disease? Yes. In August 2025, the FDA granted Wegovy accelerated approval for adults with noncirrhotic MASH and moderate-to-advanced fibrosis (stages F2–F3), used alongside diet and exercise. It is the first GLP-1 drug cleared for a liver disease.

What is MASH? Metabolic dysfunction–associated steatohepatitis — the aggressive form of fatty liver disease, in which fat drives inflammation and scarring that can progress to cirrhosis, liver failure, and cancer. It affects roughly one in twenty American adults.

What does accelerated approval mean? The FDA approved Wegovy for MASH based on biopsy improvements that are reasonably likely to predict clinical benefit. The approval is conditional: Novo must confirm, in longer-term data reading out around 2029, that those changes translate into fewer serious liver outcomes.

Sources

1. U.S. Food and Drug Administration — “FDA Approves Treatment for Serious Liver Disease Known as ‘MASH,’” August 15, 2025.
2. Novo Nordisk A/S — Wegovy MASH approval press release, August 2025.
3. Sanyal, A.J., Newsome, P.N., et al. — ESSENCE trial, New England Journal of Medicine, 2025 (NCT04822181).
4. U.S. Food and Drug Administration — resmetirom (Rezdiffra) approval for MASH, March 2024.